Updates are available Correction dated 2024-01-22
Click to view Correction: https://doi.org/10.1007/s10875-024-01655-3
-
Authors
Mustillo, Peter J. https://orcid.org/0000-0002-8420-8655
Sullivan, Kathleen E.
Chinn, Ivan K.
Notarangelo, Luigi D.
Haddad, Elie
Davies, E. Graham
de la Morena, Maria Teresa
Hartog, Nicholas
Yu, Joyce E.
Hernandez-Trujillo, Vivian P.
Ip, Winnie
Franco, Jose
Gambineri, Eleonora
Hickey, Scott E.
Varga, Elizabeth
Markert, M. Louise
- License Information
-
More Information
Article History
Received: 10 October 2022
Accepted: 4 December 2022
First Online: 17 January 2023
Change Date: 22 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10875-024-01655-3
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: PJM received past honoraria from Horizon Therapeutics (advisory board). KS serves on the Immune Deficiency Foundation. The thymic transplant description and other references of MLM relate to the work that that was funded, in part, by Enzyant Therapeutics or performed under a Sponsored Research Agreement in partnership with Enzyvant Therapeutics, GmbH. IKC reports work with Wolters Kluwer (UptoDate), past consultant for Enzyvant. NH reports COI with Horizon, speaker, advisory board; Binding Site, speaker; Takeda, speaker, advisory board; and Pharming Healthcare, advisory board, scientific steering committee. EH is a recipient of honoraria for AdBoard meetings from CSl-Behring, Octapharma, and Takeda and from DSMB from Jasper Therapeutics and owns shares in Immugenia biotech company. The other authors declare they have no conflict of interest.
: The publication of this article was supported by the Clinical Immunology Society (CIS). The content of this article does not necessarily reflect the views of the Clinical Immunology Society (CIS), nor does mention of trade names, commercial products, or organizations imply endorsement by the Clinical Immunology Society (CIS).
